These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27713349)

  • 1. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.
    Hayakawa K; Mishima K; Fujiwara M
    Pharmaceuticals (Basel); 2010 Jul; 3(7):2197-2212. PubMed ID: 27713349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Central Effect of Components of Cannabis: Utility and Risk].
    Mishima K; Irie K
    Yakugaku Zasshi; 2020; 140(2):193-204. PubMed ID: 32009043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.
    Fride E; Ponde D; Breuer A; Hanus L
    Neuropharmacology; 2005 Jun; 48(8):1117-29. PubMed ID: 15910887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
    Roser P; Vollenweider FX; Kawohl W
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
    Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
    Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phytocannabinoids as novel therapeutic agents in CNS disorders.
    Hill AJ; Williams CM; Whalley BJ; Stephens GJ
    Pharmacol Ther; 2012 Jan; 133(1):79-97. PubMed ID: 21924288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis and Neuropsychiatric Disorders: An Updated Review.
    Chayasirisobhon S
    Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Viana MB; de Aquino PEA; Estadella D; Ribeiro DA; Viana GSB
    Med Cannabis Cannabinoids; 2022; 5(1):207-219. PubMed ID: 36467781
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Watt G; Karl T
    Front Pharmacol; 2017; 8():20. PubMed ID: 28217094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
    Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
    Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.
    Fischedick J; Van Der Kooy F; Verpoorte R
    Chem Pharm Bull (Tokyo); 2010 Feb; 58(2):201-7. PubMed ID: 20118579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
    Niesink RJ; Rigter S; Koeter MW; Brunt TM
    Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in cannabis research from a pharmaceutical chemist's point of view].
    Müller CE
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Jul; 62(7):818-824. PubMed ID: 31161229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of cannabinoids in CNS disease.
    Croxford JL
    CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.
    Martín-Moreno AM; Reigada D; Ramírez BG; Mechoulam R; Innamorato N; Cuadrado A; de Ceballos ML
    Mol Pharmacol; 2011 Jun; 79(6):964-73. PubMed ID: 21350020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacological characterization of Cannabis sativa chemovar extracts.
    Devsi A; Kiyota B; Ouellette T; Hegle AP; Rivera-Acevedo RE; Wong J; Dong Y; Pugsley MK; Fung T
    J Cannabis Res; 2020 May; 2(1):17. PubMed ID: 33526117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism.
    Hayakawa K; Mishima K; Nozako M; Hazekawa M; Irie K; Fujioka M; Orito K; Abe K; Hasebe N; Egashira N; Iwasaki K; Fujiwara M
    J Neurochem; 2007 Sep; 102(5):1488-1496. PubMed ID: 17437545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.